Larazotide

The clinical development arc for larazotide is the most informative recent worked example in the gut-permeability peptide space, and the failed-peptide-trials archive and IBD-and-peptides dossier both flag the molecule for that reason. The program ran from a 2007 first-in-human proof-of-concept study through a positive Phase IIb signal in 2015 and ended in a Phase III futility analysis in 2022.

The earliest human study is Paterson, Lammers, Arrieta, Fasano, and Meddings, Aliment Pharmacol Ther 2007, 26:757–766, a 21-subject double-blind randomised placebo-controlled gluten-challenge trial in adults with celiac disease (14 on AT-1001, 7 on placebo) that measured intestinal permeability via lactulose-mannitol fractional excretion. The placebo arm showed a 70% increase in permeability following acute gluten exposure; the AT-1001 arm showed no such increase, and gastrointestinal symptoms were more frequent on placebo. The trial established acute pharmacodynamic activity on a permeability biomarker and supported further development. The follow-up Phase 2 dose-ranging study by Leffler, Kelly, Abdallah et al., Am J Gastroenterol 2012, 107:1554–1562 extended the gluten-challenge design to 86 celiac patients; the permeability measure proved too variable for reliable assessment, but lower doses limited gluten-induced worsening of GI symptom severity while the highest dose did not. Kelly, Green, Murray, DiMarino, Colatrella, Leffler et al., Aliment Pharmacol Ther 2013, 37:252–262 ran a larger gluten-challenge trial in 184 patients with three doses (1, 4, or 8 mg three times daily) and found that the 1-mg arm reduced gluten-induced symptoms significantly (p = 0.002) and reduced anti-tissue transglutaminase antibody responses across doses, while permeability measures did not separate from placebo — already a foreshadowing of the pattern that would recur at scale.

The Phase IIb pivotal-supporting trial is Leffler, Kelly, Green, Fedorak, DiMarino, Perrow, Rasmussen, Wang, Bercik, Bachir, and Murray, Gastroenterology 2015, 148:1311–1319.e6, a randomised double-blind placebo-controlled study in 342 adults with celiac disease who continued to experience symptoms despite ≥12 months on a gluten-free diet. The design included a 4-week placebo run-in, a 12-week treatment phase at 0.5, 1, or 2 mg three times daily, and a 4-week placebo run-out, with the primary endpoint defined on the Celiac Disease Gastrointestinal Symptom Rating Scale (CeD-GSRS). The 0.5-mg dose met the prespecified primary endpoint with improvement on CeD-GSRS versus placebo (ANCOVA p = 0.022; mixed model p = 0.005); the 1-mg and 2-mg doses produced no separation from placebo, an inverted dose-response the authors did not entirely resolve. The result was sufficient to justify Phase III investment.

The Phase III trial — CeD-PRO, NCT04486313, sponsored by 9 Meters Biopharma after acquiring the molecule from Alba Therapeutics — was designed to randomise approximately 525 patients to larazotide 0.25 mg, larazotide 0.5 mg, or placebo three times daily, with a 5-week screening period, a 12-week double-blind treatment phase, and a 12-week continued safety phase. The primary endpoint was mean change from baseline in CeD-PRO abdominal-domain score over 12 weeks. On June 21, 2022, 9 Meters Biopharma announced that an independent statistician's interim analysis at approximately 50% enrolment had concluded the additional sample size required to demonstrate a statistically significant treatment effect was prohibitively large; the trial was discontinued for futility. No successor sponsor has advanced the molecule for celiac disease, and Alba Therapeutics' original program — which had at one point included broader autoimmune and IBD framing — was effectively closed at the Phase III readout.

The contrast that sharpens the development reading is teduglutide (Gattex / Revestive). Jeppesen, Pertkiewicz, Messing et al., Gastroenterology 2012, 143:1473–1481.e3 — the STEPS Phase III pivotal — supported FDA approval in 2012 of a recombinant GLP-2 analog for short bowel syndrome with intestinal failure, on a mucosal-growth mechanism with directly relevant endpoint design (reduction in weekly parenteral support volume). The two molecules — larazotide and teduglutide — both targeted intestinal-epithelial pharmacology, both reached Phase III, and only one converted that trajectory into a marketed product. The differences worth registering are the indication's endpoint clarity (parenteral-support reduction is a structurally less noisy measure than patient-reported symptom severity in a chronic dietary-controlled condition), the mechanism's coupling to the trial population (GLP-2 receptor agonism produces measurable mucosal-growth changes in patients whose underlying pathology is mucosal insufficiency, in a way that tight-junction modulation in patients adherent to a gluten-free diet is not similarly coupled), and the sample-size adequacy to detect the effect actually present.

The off-label and gray-market interest in larazotide outside celiac disease persists despite the Phase III outcome. The peptide circulates in patient communities focused on IBD, "leaky gut" framings, autoimmune conditions where intestinal-barrier hypotheses are advanced, and post-COVID multisystem-inflammatory presentations. The single notable publication in that broader space is Yonker, Boucau, Regan et al., Crit Care Explor 2022, 4:e0641 — an open-label four-patient case series of larazotide as adjuvant treatment in pediatric multisystem inflammatory syndrome (MIS-C) with reduction in SARS-CoV-2 spike antigenaemia and faster symptom resolution compared to historical controls. The case series is hypothesis-generating, not trial-grade. No completed Phase II RCT supports larazotide use in IBD, autoimmune disease, MIS-C, or any indication outside the failed celiac program. The mechanistic argument that tight-junction regulation should generalise across barrier-dysfunction-implicated conditions (Sturgeon and Fasano, Tissue Barriers 2016, 4:e1251384) is plausible at the mechanism level and unsupported at the trial-evidence level.

The honest framing: larazotide is mechanistically interesting — a first-in-class luminal peptide whose acid-resistant design and locally-acting pharmacology were well-engineered for the indication — and clinically disappointing. The Phase IIb signal at the 0.5-mg dose did not replicate at scale. The molecule's place in the modern peptide field is as a worked example of how a credible mechanism plus a positive mid-phase trial can still fail to produce a Phase III result and a marketed product. Readers extrapolating from the celiac IIb to applied IBD or "leaky gut" use are reasoning past where the trial evidence stops. The KPV entry walks the parallel case of a gut-targeted peptide with strong preclinical IBD evidence and no completed human trial; the BPC-157 entry walks the case of a peptide whose Phase II ulcerative-colitis program (PL 14736) reached the same stage as larazotide's Phase IIb but did not produce a published result either way.